Background: Traditional medicine has long utilized herbal and animal-derived materials worldwide, and traditional formulations for the management of male sexual dysfunction continue to be actively investigated. This study aimed to investigate the chemical composition and antioxidant effects of Anti-Impotence-4, an herbal–animal formulation, in an experimental model of chronic stress-induced erectile dysfunction (ED). Aim: To investigate the bioactive compounds present in the plant- and animal-derived formulation Anti-Impotence-4 and its effects against oxidative stress. Materials and Methods: Fifty-eight male Wistar rats were randomly divided into six groups, including healthy control, disease control, reference, and treatment groups. Chronic stress was induced once daily for 56 days using a random stress protocol, as described by Peng Zou (2019). Oxidative stress parameters were determined using ELISA. The chemical constituents of the methanolic extract of Anti-Impotence-4 were analyzed using ultra-performance liquid chromatogra phy–mass spectrometry (UPLC–MS) in both positive and negative ionization modes. Results: In an experimental model of erectile dysfunction induced by chronic stress, treatment with Anti-Impotence-4 led to a dose-dependent attenuation of oxidative damage. Specifically, levels of the DNA oxidation marker 8-hydroxy-2′-de oxyguanosine (8-OHdG) were reduced by 13.3–32.5% following administration of Anti-Impotence-4 at doses of 42, 84, and 210 mg/kg. Likewise, malondialdehyde (MDA) concentrations decreased by 7.9–23.7% at therapeutic doses (p<0.05). In contrast, antioxidant defense mechanisms were markedly enhanced, as evidenced by significant increases in superoxide dismutase (SOD) activity (34.1%, 38.1%, and 44.6%, respectively; p<0.05) and glutathione (GSH) levels, which rose by 37.0–55.4%. Biological substances identified a total of 10 compounds, including six amino acids, flavo noids, and iridoids, in the positive ion mode. In negative-ion mode, 18 bioactive compounds were detected, including amino acids, carbohydrates, organic acids, fatty acids, flavonoids, and phenolic compounds. Conclusion Phytochemical analysis of the methanolic extract of the Anti-Impotence-4 formulation demonstrated the presence of diverse bioactive constituents, including amino acids, purine derivatives, nucleosides, carbohydrates, organic and fatty acids, flavonoids, phenolic compounds, and iridoids. In a chronic stress-induced erectile dysfunction model, treatment with Anti-Impotence-4 significantly enhanced antioxidant defense by increasing superoxide dismutase and glutathione levels, while markedly reducing oxidative stress markers such as 8-hydroxy-2′-deoxyguanosine and malond ialdehe indicating significant antioxidant and protective effects.

Background: According to classical sources of Traditional Mongolian Medicine, the Mana-4 decoction clears internal heat and fever, alleviates febrile and infectious diseases, resolves pale-brown Badgan disorders, and alleviates severe pneumonia. Chimedragchaa.Ch. et al. (2002) demonstrated that Mana-4 possesses heat-clearing, anti-inflammatory, and immunomodulatory effects. Chronic Fatigue Syndrome (CFS) is a disorder characterized by clinical manifestations including physical exhaustion, low-grade fever, headache, mood fluctuations, cognitive impairment, and sleep disturbances. In recent years, as the pace of modern life and workload have increased, physical, psychological, and mental stress have intensified, leading to dysregulation of the nervous and endocrine systems, impaired immune function, and a rising global prevalence of CFS—a trend that has attracted increasing attention from researchers worldwide. However, the etiology and pathogenesis of CFS remain incompletely understood, and effective, evidence-based treatments continue to be sought. Therefore, we developed Immunoflu soluble granules, derived from the constituents of Mana-4, and this study aimed to investigate its anti-fatigue effects, as no such investigation had previously been conducted. Aim: To evaluate the anti-fatigue effect of Immunoflu, a formulation derived from the traditional Mana-4 decoction widely used in Traditional Mongolian Medicine. Materials and Methods: A chronic-fatigue rat model was established by forced-swimming induction, following the method of Jia Wang et al. (2013). The behavioral effects of Immunoflu were assessed using the open-field test (locomotor activity) and the elevated plus-maze test (anxiety-related behavior). Result: Immunoflu was administered at 100, 200, and 400 mg/kg to evaluate its effects in a chronic-fatigue model. In the open-field test, no significant difference (p>0.05) in central-zone entries was observed between Immunoflu and the model control. However, vertical locomotor activity increased significantly: Immunal 50 mg/kg +80.4% (p=0.024), Immunoflu 100 mg/kg +82.6% (p=0.003), and 200 mg/kg +77.4% (p=0.035). From these findings, Immunoflu at 100 and 200 mg/kg clearly enhanced locomotor activity in rats with chronic fatigue. In the elevated plus-maze test, Immunal 50 mg/kg increased the time spent in the central zone (10×10cm) by 53.3% (p=0.021) and in open arms by 61.4% (p=0.032) compared with the model control. Although Immunoflu produced no significant changes (p>0.05) in central-zone entries or time spent in the central zone, the time spent in the open arms increased by 60.6% at 200 mg/kg (p=0.026), indicating a reduction in anxiety and improved behavioral response to stress. Conclusion In a forced-swimming–induced chronic-fatigue model, Immunoflu increased locomotor activity by 77.4–82.6% at 100 and 200 mg/kg, reduced anxiety by 60.6% at 200 mg/kg, and reduced behavioral despair and fatigue by 35.3% at 100 mg/kg.

Background: Diabetes mellitus accounts for 42.9% of endocrine and nutritional metabolic diseases in Mongolia, with a prevalence of 111.4 cases per 10,000 population. This represents a 28.5% increase compared with the previous year (82.9 cases per 10,000 population in 2019), indicating a continuing upward trend in the prevalence of diabetes mellitus. In Mongolian traditional medicine, Sapparin tablets are used to treat blood disorders and liver diseases. The formulation contains four major herbal ingredients: C. jubata, C. sappan, Z. officinale, and H. rhamnoides. Aim: To study the effects of Sapparin in a high-fat diet and low-dose streptozotocin-induced diabetic model in experimental rats. Materials and Methods: We used 40 Wistar rats to establish a type 2 diabetes mellitus (T2DM) model according to the method described by Bailu Duan et al. (2017). The rats were fed a high-fat diet for 28 days, followed by an intraperitoneal injection of streptozotocin (STZ) at 35 mg/kg to induce T2DM. After STZ administration, Sapparin was orally administered to diabetic rats at 89 and 178 mg/kg for 21 days. At the end of the experimental period, insulin, GLUT4, superoxide dismutase (SOD), and glucagon-like peptide-1 (GLP-1) levels were determined using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions on days 14 and 21. Result: After 14 and 21 days of treatment, fasting blood glucose levels decreased by 33% and 22.5% in the Sapparin 89 mg/kg and 178 mg/kg groups, respectively, compared with the diabetic control group (p=0.05). In the glucose tolerance test, the 89 mg/kg Sapparin-treated group showed a 31% increase in glucose levels at the initial measurement compared with the diabetic control group, followed by decreases of 10% at 30 min and 30% at 120 min (p=0.04). Serum insulin levels in the 89 mg/kg Sapparin group decreased by 20% on day 14 and 19.8% on day 21 compared with the diabetic control group, while the 178 mg/kg group showed decreases of 15% and 20%, respectively, approaching the levels observed in the healthy control group (p=0.05). Furthermore, HOMA-IR decreased by 42–46% over time in both the 89 and 178 mg/ kg Sapparin-treated groups, with statistically significant differences observed (p=0.05). Conclusion In a rat model of type 2 diabetes mellitus, Sapparin reduced blood glucose levels, serum insulin levels, and insulin resistance (HOMA-IR), and may have a positive effect on lipid metabolism.

Background: Respiratory diseases remain among the top five leading causes of morbidity, with an incidence rate of 788.4 cases per 10,000 population in 2021. Among these, acute bronchitis accounts for 9.3%. According to international clinical guidelines for the diagnosis and treatment of adult acute bronchitis, symptoms usually resolve spontaneously within 1–3 weeks, but they considerably reduce the patient’s quality of life. Therefore, Colsaurin syrup, a new natural formulation with analgesic and anti-inflammatory effects, was clinically investigated to assess its efficacy and safety. The introduction of this domestically produced herbal medicine into clinical practice is expected to have both medical and socioeconomic significance by expanding the range of national pharmaceutical products. Aim: To evaluate the effect of Colsaurin syrup on the quality of life in adults diagnosed with acute bronchitis. Materials and Methods: This study was a randomized, double-blind, placebo-controlled clinical trial conducted among inpatients at Songinokhairkhan District General Hospital, Ulaanbaatar. Adult patients diagnosed with acute bronchitis (J20) who met the inclusion criteria and provided informed consent were enrolled. Participants were randomly assigned to either the Colsaurin or placebo group. Result: In the Bronchitis Severity Score (BBS) assessment, baseline mean scores indicated severe disease: 10.88±2.47 in the Colsaurin group and 10.67±2.16 in the placebo group. After treatment, scores decreased significantly to 3.50±1.41 (p<0.001) in the Colsaurin group and 5.00±2.24 (p=0.006) in the placebo group, indicating greater improvement in the Colsaurin-treated patients. In the Visual Analog Scale (VAS) assessment, the mean pre-treatment score for both groups was 7, corresponding to frequent cough, which decreased to 2 after treatment (p<0.05), representing a 28% reduction in coughing discomfort. In the Cough and Sputum Assessment Questionnaire (CASA-Q), the Colsaurin group showed a 3.25-point reduction after treatment, indicating a significant decrease in cough frequency and triggering factors (p<0.05). Conclusion 1. In patients diagnosed with acute bronchitis (J20), treatment with Colsaurin syrup reduced disease severity by 30% and alleviated cough-related discomfort by 28% compared to baseline. 2. Moreover, patients reported improved sleep quality and work capacity, reflecting an overall enhancement in quality of life. 3. No adverse effects were observed in the Colsaurin treatment group.

Background: Chronic Fatigue Syndrome (CFS) is a poorly understood disorder of unknown etiology, characterized by clinical manifestations including physical exhaustion, low-grade fever, myalgia, dizziness, mood fluctuations, cognitive impairment, and sleep disturbances. CFS is highly prevalent and frequently comorbid with psychiatric conditions, particularly depression and anxiety. Symptoms exacerbate during physical or mental exertion and do not completely resolve with rest. Currently, there is a lack of proven, effective pharmacological treatments for CFS. Therefore, this study aimed to investigate the anti-fatigue effects of Immunoflu. Aim: To evaluate the anti-fatigue effects of Immunoflu, a technologically modernized formulation derived from the traditional Mana-4 decoction. Materials and Methods: A chronic fatigue rat model was established using the forced-swim protocol described by Jia Wang and Chengxin Sun (2013). The pharmacological effects of Immunoflu were evaluated by quantifying serum levels of cytokines (IL-1β, IL-2, IL-5, IL-10, and IL-17a) by ELISA and assessing behavioral despair using the forced swim test (FST). Results: We evaluated how Immunoflu affects the chronic fatigue model at doses of 100, 200, and 400 mg/kg by measuring serum levels of IL-1β, IL-2, IL-5, IL-10, and IL-17a and assessing despair using the “Forced swim test”. In the forced-swimming-induced chronic fatigue model in rats, Immunoflu at a dose of 100 mg/kg increased the serum IL-2 indicator by 23.8%, and Immunal at a dose of 50 mg/kg increased it by 23.3% compared to the model control group, a statistically significant difference (p < 0.05). Furthermore, Immunoflu at 200 mg/kg reduced IL-17a cytokine levels by 23.7% compared with the model control group. When evaluating the swimming state of the animals with the Forced swim test, the group given Immunal 50 mg/kg (52.03±9.3 sec) decreased by 31.6% (*p=0.038), and the group given Immunoflu 100 mg/kg (49.19±8.54 sec) decreased by 35.3% (*p=0.01) respectively compared to the model control group, while no statistically significant difference was observed in other groups. Conclusions 1. Immunoflu at 100 mg/kg demonstrates immunostimulatory effects in a chronic fatigue model by increasing serum IL-2 levels by 23.8%. Additionally, at 200 mg/kg, it exhibits anti-inflammatory properties, reducing IL-17a levels by 23.7%. 2. In the forced-swimming model, Immunoflu at 100 mg/kg effectively reduced behavioral despair and physical fatigue by 35.3%.

Diabetes, hyperlipidemia, and hyperuricemia have emerged as global chronic metabolic disorders posing significant public health challenges. Edible medicinal plants demonstrate multitarget regulatory effects and favorable safety profiles in the management of chronic metabolic diseases, owing to their bioactive compounds and nutritional synergy. Radix Astragali (RA), a traditional Chinese medicine with medicine–food homology, has a long history of application in China. Based on a review of relevant literature, this article discusses the historical background, modern research, therapeutic functions, and mechanisms of RA in the treatment of chronic metabolic diseases. Modern studies have shown that RA contains a variety of bioactive components and demonstrates efficacy in managing diabetes, hyperlipidemia, and hyperuricemia. Its mechanisms of action involve modulation of the insulin signaling pathway, regulation of lipid metabolism-related enzyme activity, promotion of uric acid excretion, and other processes. Notably, RA exhibits certain common therapeutic effects across hyperglycemia, hyperlipidemia, and hyperuricemia. Through modulation of the gut microbiota and inhibition of inflammatory pathways, RA exerts synergistic, multitarget effects that improve metabolic disorders associated with chronic metabolic diseases.

Background: Medicines with unique healing methods and European medical treatments and services, which have been used around the world to this day, are now being used in a combined form in the healthcare services of many countries, and the possibility of integrating them is a widely discussed issue among researchers. It is noteworthy that no independent research has yet been published that has analyzed in detail how the influence of Chinese and other medical schools has been reflected in the development of Traditional Mongolian medicine. It is considered important to analyze this issue individually, in each direction, to clarify the historical process of how Traditional Mongolian medicine was formed today. Aim: Conduct research within specific codes in the works of Mongolian doctors to identify the presence of Chinese medical data, knowledge, and information. Materials and Methods: The research was conducted using a qualitative research method based on historical and source books. Our study employed content and thematic analysis, utilizing coding and the identification of recurring patterns in the source text. Results: The results of the coding study show that most of the data used from Chinese meicines falls under the code “infection”. In Sumbe Khamba Ishbaljir’s sourcebook, 42.8% of the information was coded as infection, in Tsakhar Gevsh Luvsanchultemi’s sourcebook 50%, in Mindol Khutagt Jambalchoyjidanzanperenle’s sourcebook 47.05%, and in Ishdanzanvanjil’s “Shuren Chimeg” 87.5% was coded as infection. After that, when the information included in the code “injury” is classified by each sourcebooks, 33.3% is found in Ishbaljir’s sourcebook, 0% in Luvsanchultem, 24% in Min dol Khutagt Jambalchoyjidanzanperenley, and 6.25% in Ishdanzanvanjil, which ranks second among all codes. Conclusion 1. According to the research results, 56.66% of the Chinese medical information in the above works is related to infection cases. 2. The integration of Chinese medicine learning with Traditional Mongolian medicine methods during epidemics such as “Bodoo” may be a major influencing factor that has shaped the current integrative medicine process.

Background: In traditional medicine, Jur Ur-4 Tang, which is widely used for the treatment of diabetes, has been technologically processed and transformed into a modern pharmaceutical form as soluble granules. Therefore, it is essential to evaluate the pharmacological effects of the soluble granules derived from Jur Ur-4 Tang. Aim: To study the effect of granules extracted from Jur ur-4 Tang in a model of type 2 diabetes mellitus in experimental rats. : Materials and Methods : T2DM in rats was induced by a high-fat diet and a low-dose streptozotocin (STZ 35 mg/kg). Then, oral gavage administration of three different doses of Granule (450 mg/kg, 900 mg/kg) was given to T2DM rats. Experimental results showed that Granule dramatically reduced the levels of fasting blood glucose, fasting blood insulin, and GLUT4. Results:: In the glucose tolerance test, granules at doses of 450 and 900 mg/ kg significantly reduced blood glucose levels at 60 and 120 minutes (p < 0.01). Additionally, the soluble granules at all tested doses significantly decreased blood insulin levels and increased GLUT4 expression (p<0.01). Conclusion The granules lower blood glucose levels.

Background: Social development due to fat, fast food, obesity and physical exercise depended on chronic cholecystitis and gallstones, still getting younger in recent years. Yaman Serdeg-3 is used in Mongolian Traditional Medicine for the liver and gallbladder and has been studied to support the excretion of bile. We have created a compound recipe, Yaman Serdeg-3 of Mongolia Traditional medicine, added Saussurea amara (L)DC herbal. Saussurea amara (L). DC is high in biologically active compounds, and pharmacology has investigated the bile-expelling action and the effects of the plant on cell growth. Chronic cholecystitis is a common chronic disease of the biliary tract in clinical patients. Symptoms can be seen in right upper abdominal cramps; some patients can be accompanied by abdominal muscle rigidity, the primary disease. It is caused by a large amount of bile blocking the patient’s gallbladder after the stone blocks the gallbladder duct. In the sac, induced acute cholecystitis was again caused by pathogenic factors to form the disease. Aim: Elucidating the effects of supplemental Yaman serdeg-3 in a gallbladder injury model. Materials and Methods: We received permission for animal experimentation from The Ethics Committee of Mongolia National University of Medical Sciences on the 10th of June 2022. The group created a model gallbladder disease with 0.5% a-naphthyl isothiocyanate [C11H7N5] dose (60 ml/kg), treatment with compound recipe Yaman Serdeg-3 (NYS-3) high dose (2.025 g/ml), medium dose (1.35g/ml), low dose (0.675g/ml), that used to compare URSO 250 (0.0042g/ml) for 21 days. The third group created a model liver disease with a 40% Carbon tetrachloride [CCl4] dose (4 ml/kg), treatment with compound recipe NYS-3 high dose (2.025 g/ml) and that was used to compare Hu gan pian (0.046g/ml) of China medicine for 21 days. Liver tissue pathological sections were collected quickly after blood collection in rats. The liver, stomach, and duodenum tissue on the right page were immersed in 10% neutral formalin and fixed for pathology. Histological examination: The fixed tissue was trimmed, dehydrated, embedded, and cut. After slides, HE staining, sealing, and other procedures, an optical microscope was used to observe. Results: In our study, the structure of the liver tissue cells in the high-dose group of Yaman serdeg-3 was preserved, the vessels had irregular blood vessels, and there was significant infiltration of chronic inflammation in the triple bypass. In this group, we divided the Yaman serged-3 into three groups: low-dose, medium-dose, and high-dose. In the model group with liver tissue analysis, the low-dose and medium-dose groups had fewer chronic inflammatory cells in triads and interstitial cells. In contrast, the fact that the high-dose group of Yaman serdeg-3 showed sparse trigeminal and interstitial and very few chronic inflammatory cells indicates that our study met its objectives, and the tissue analysis showed that the high-dose group was more effective. Conclusion During the acute and toxic liver disease model in rats, the inflammation process in the liver cells was high, and watery changes and fatty changes damaged the liver tissue. It has been confirmed that traditional herbal medicine, Yaman serdeg-3, reduced protein and fatty tissue changes in the hepatocyte membrane and accelerated liver and biliary tract regeneration. Furthermore, our study has shown that Yaman serdeg-3 may have stimulated bile secretion dose-dependently and accelerated hepatocyte regeneration. Also, liver tissue analysis of the control group showed significant inflammation in the triad and interstitial cells; blood vessels were filled with blood, and cell structure was preserved. In contrast, the comparison drug group had significant triad inflammation and fewer inflammatory cells in the interstitial cells.

Background: Lish-6 has been used for treatment pharyngitis, flu and throat disease. Lish-6 is composed from Eugenia caryophylla. Thumb, Saussurea lappa C.B. Clark, Schizostachoum chinense. Rendle, Glycyrrhiza uralensis. Fisch, Gentiana algida Pall, Terminalia chebula. Retz. Anti-fever properties of these plants and their bio-active compounds have extensively been studied. Aim: To determine the anti-fever effects of Lish-6. Marerials and Methods: Fever was induced by intravenous administration of lipopolysaccharide (LPS) at concentration of 0.5 mg/kg. Lish-6 was given orally at concentration of 92 mg/kg, 1 and 6 hours after the LPS administration. Rectal temperature wa measured 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 hours after the LPS administration. Paracetamoli was given orally at concentration of 50 mg/kg. Blood levels of Prostaglandin E2 (PGE2) and interleukin-6 (IL-6) interleukin-1β (IL-1β) were determined by enzyme linked immune sorbent assay using rat kits. Lung tissue was examined by histopathological analysis. Results: The body temperature of rats in the normal group was 35.0±1.10С, while in the control group, periodic fever was caused by the effect of lipopolysaccharide (p=0.001). But in the Lish-6 drug group, rectal temperature decreased steadily (p=0.05). In addition, the IL-1β cytokine in the normal group was 3.24±0.31 ng/L and increased by 60.5% in the control, indicating the development of the pathological model, while this parameter decreased by 31% in the Lish-6 drug group (p=0.05). IL-6 cytokine in the normal animals was 21.1±0.2 pg/L and increased by 19.04% in the control, indicating the development of the pathological model, while this parameter decreased by 8.3% in the Lish-6 drug group (p =0.05). PGE2 in the normal group was 43.2±0.3 ng/L, and it increased by 62.7% in the control group, indicating the development of a pathological model, while this parameter decreased by 53.3% in the Lish-6 drug group (p=0.05). Conclusion Lish-6 traditional drug has the effect of reducing rectal temperature, IL-1β, PGE2 and IL-6 cytokines during lipopolysaccharide-induced febrile pathology model.